Dr. Alex Giaquinto Joins Biothera Board of Directors

EAGAN, Minn., Jun 09, 2008 (BUSINESS WIRE) -- Alex Giaquinto, Ph.D., a former Schering-Plough senior executive, has joined the Biothera Board of Directors, the company announced today. Biothera is a biotechnology company developing pharmaceuticals and functional food ingredients based on a unique technology that engages and directs the innate immune system.

Dr. Giaquinto's extensive pharmaceutical industry experience includes positions as Senior Vice President of Worldwide Regulatory Affairs at Schering-Plough Research Institute and the Senior Vice President of Global Compliance at Schering-Plough Corporation. He also has held numerous professional and academic positions, including Chairman of the Regulatory Affairs Coordinating Committee of the Pharmaceutical Research and Manufacturers Association, a lecturer on drug law at Temple University, and advisor to the University of Texas regarding its International Conference for Drug Development. Dr. Giaquinto is currently a special advisor to Tunnell Consulting, an integrative consulting company focused on life sciences.

"Alex Giaquinto's tremendous pharmaceutical experience and expertise will help guide Biothera's efforts to bring Imprime PGG(R) through the FDA regulatory approval process," said Daniel K. Conners, Biothera Chairman and Founder.
Biothera is currently conducting a clinical trial in metastatic colorectal cancer patients with a combination of Imprime PGG, Erbitux(R) (cetuximab) and Comptosar (irinotecan). A trial in lung cancer patients receiving Imprime PGG, Avastin(R) (bevacizumab) and two chemotherapy drugs -- Taxol (paclitaxel) and Paraplatin (carboplatin) -- is expected to begin in the second quarter of 2008.

Dr. Giaquinto received a doctorate in Pharmaceutics from the University of Connecticut and a bachelor's degree in Pharmacy from the St. John's University College of Pharmacy.

About Biothera, the Immune Health Company
Biothera is a biotechnology company dedicated to improving immune health. The company is developing pharmaceuticals that engage the innate immune system to fight cancer. Biothera also manufactures and markets Wellmune WGP(R) and other food-grade ingredients that support healthy immune function to the nutritional supplement, functional food, cosmetic and animal nutrition markets. ( www.biothera.com)

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.